ADMA

Adma Biologics Inc

Healthcare


Presented:04/11/2024
Price:$6.22
Cap:$1.42B
Current Price:$16.58
Cap:$3.86B

Presented

Date04/11/2024
Price$6.22
Market Cap$1.42B
Ent Value$1.11B
P/E RatioN/A
Book Value$0.60
Div Yield0%
Shares O/S228.22M
Ave Daily Vol2,573,912
Short Int3.35%

Current

Price$16.58
Market Cap$3.86B
ADMA Biologics, Inc. operates as a biopharmaceutical company, which is engaged in manufacturing, marketing, and developing specialty plasma-derived biologics. The firm operates through the following business segments: ADMA BioManufacturing, Plasma Collection Center, and Corporate. The ADMA BioManufacturing segment consists of immune globulin manufacturing and development operations. The Plasma Collection Center consists of source plasma collection facilities. The Corporate segment includes general and administrative overhead expenses. The company was founded by Adam S. Grossman and Jerrold B. Grossman on June 24, 2004 and is headquartered in Ramsey, NJ.

Publicly traded companies mentioned herein: ADMA Biologics Inc (ADMA)

Highlights

The presenter is long shares of ADMA Biologics Inc (ADMA), and sees the company poised for significant growth and valuation expansion, driven by its differentiated product offerings and strategic position within the immunoglobulin (IG) market. Given the company’s nearly 70% revenue growth in 2023 there should be upside to the current valuation of 12x consensus 2025 EPS. He thinks the fundamentals could support a $2.5B market cap vs today’s $1.5B. 

  • Signing up and creating account with us unlocks this content for you. Contact us today for full access to DeMatteo Research and more.

  • Signing up and creating account with us unlocks this content for you. Contact us today for full access to DeMatteo Research and more.

Request access to DeMatteo Research for full access

Request Access

Already have an account?

Idea Discussion

Commentor 1 - 2 weeks ago

Signing up and creating account with us, unlocks this content for you. Contact us today for full access to DeMatteo Research and more.

Commentor 1 - 2 weeks ago

Signing up and creating account with us, unlocks this content for you. Contact us today for full access to DeMatteo Research and more.

Idea Discussions display submitted commentary from our investor community.

To read and participate in the discussion with the presenter and investor base, request access to DeMatteo

Request Access

Already have an account?

An error occurred loading this content. Try again later or contact us.